{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:35Z","timestamp":1791237815841,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403889"],"award-info":[{"award-number":["82403889"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763899"],"award-info":[{"award-number":["2024M763899"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04537-5","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:23:21Z","timestamp":1778477001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Folic acid-modified antigen-trapping nanoprobes for developing in situ tumor vaccines to inhibit metastasis and recurrence of ovarian cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaowen","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4537_CR1","first-page":"240","volume":"20","author":"R Porter","year":"2022","unstructured":"Porter R, Matulonis UA. Immunotherapy for ovarian cancer. Clin Adv Hematol Oncol. 2022;20:240\u201353.","journal-title":"Clin Adv Hematol Oncol"},{"key":"4537_CR2","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70043.","journal-title":"CA Cancer J Clin"},{"key":"4537_CR3","volume":"7","author":"K Ksi\u0105\u017cek","year":"2021","unstructured":"Ksi\u0105\u017cek K. Molecular biology of ovarian cancer: from mechanisms of intraperitoneal metastasis to therapeutic opportunities. Cancers (Basel). 2021;7:13.","journal-title":"Cancers (Basel)"},{"key":"4537_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41416-023-02321-y","volume":"129","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu Z, Yang Y, Cui J, Sun J, Liu Y. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. Br J Cancer. 2023;129:1041\u20139.","journal-title":"Br J Cancer"},{"key":"4537_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi N, Jaffee EM, Yarchoan M. Recent advances in therapeutic cancer vaccines. Nat Rev Cancer. 2025;25:517\u201333.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4537_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555\u201370.","journal-title":"Mol Ther"},{"key":"4537_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102383","volume":"106","author":"H Fritah","year":"2022","unstructured":"Fritah H, Rovelli R, Chiang CL, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 2022;106:102383.","journal-title":"Cancer Treat Rev"},{"key":"4537_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102611118","volume":"118","author":"DM Lussier","year":"2021","unstructured":"Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A. 2021;118:e2102611118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4537_CR9","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1021\/acsnano.2c09685","volume":"17","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wu Y, Li L, Ma C, Zhang S, Lin S, et al. Chemotherapy-sensitized in situ vaccination for malignant osteosarcoma enabled by bioinspired calcium phosphonate nanoagents. ACS Nano. 2023;17:6247\u201360.","journal-title":"ACS Nano"},{"key":"4537_CR10","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1021\/acsnano.9b02071","volume":"13","author":"QV Le","year":"2019","unstructured":"Le QV, Suh J, Choi JJ, Park GT, Lee JW, Shim G, et al. Situ nanoadjuvant-assembled tumor vaccine for preventing long-term recurrence. ACS Nano. 2019;13:7442\u201362.","journal-title":"ACS Nano"},{"key":"4537_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12951-021-00880-x","volume":"7","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhang J, Xu L, Zhuang Z, Liu J, Liu S, Wu Y, Gong A, Zhang M, Du F. NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses. J Nanobiotechnol. 2021;7:142.","journal-title":"J Nanobiotechnol"},{"key":"4537_CR12","doi-asserted-by":"publisher","first-page":"e2407914","DOI":"10.1002\/adma.202407914","volume":"36","author":"Y Huang","year":"2024","unstructured":"Huang Y, Zou J, Huo J, Zhang M, Yang Y. Sulfate Radical Based In Situ Vaccine Boosts Systemic Antitumor Immunity via Concurrent Activation of Necroptosis and STING Pathway. Adv Mater. 2024;36:e2407914.","journal-title":"Adv Mater"},{"key":"4537_CR13","first-page":"387","volume":"16","author":"Q You","year":"2025","unstructured":"You Q, Wu G, Li H, Liu J, Cao F, Ding L, Liang F, Zhou B, Ma L, Zhu L, Wang C, Yang Y, Chen X. A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Nat Nanotechnol. 2025;16:387\u2013400.","journal-title":"Nat Nanotechnol"},{"key":"4537_CR14","first-page":"568","volume":"7","author":"B Li","year":"2023","unstructured":"Li B, Jiang AY, Raji I, Atyeo C, Raimondo TM, Gordon AGR, Rhym LH, Samad T, MacIsaac C, Witten J, Mughal H, Chicz TM, Xu Y, McNamara RP, Bhatia S, Alter G, Langer R, Anderson DG. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nat Biomed Eng. 2023;7:568\u201381.","journal-title":"Nat Biomed Eng"},{"key":"4537_CR15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"4537_CR16","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM, Wherry EJ. CD8\u2009+\u2009T cells in the cancer-immunity cycle. Immunity. 2023;56:2231\u201353.","journal-title":"Immunity"},{"key":"4537_CR17","volume":"34","author":"M Marriott","year":"2023","unstructured":"Marriott M, Post B, Chablani L. A comparison of cancer vaccine adjuvants in clinical trials. Cancer Treat Res Commun. 2023;34:100667.","journal-title":"Cancer Treat Res Commun"},{"key":"4537_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113984","volume":"385","author":"J Zheng","year":"2025","unstructured":"Zheng J, Li X, He A, Zhang Y, Yang Y, Dang M, et al. In situ antigen-capture strategies for enhancing dendritic cell-mediated anti-tumor immunity. J Control Release. 2025;385:113984.","journal-title":"J Control Release"},{"key":"4537_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"4537_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"YT Liu","year":"2025","unstructured":"Liu YT, Wang YL, Wang S, Li JJ, He W, Fan XJ, Wan XB. Turning cold tumors into hot tumors to ignite immunotherapy. Mol Cancer. 2025;24:254.","journal-title":"Mol Cancer"},{"key":"4537_CR21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2337\/dbi18-0052","volume":"68","author":"J Bai","year":"2019","unstructured":"Bai J, Liu F. The cGAS-cGAMP-STING pathway: A molecular link between immunity and metabolism. Diabetes. 2019;68:1099\u2013108.","journal-title":"Diabetes"},{"key":"4537_CR22","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/med.22016","volume":"44","author":"X Tian","year":"2024","unstructured":"Tian X, Ai J, Tian X, Wei X. cGAS-STING pathway agonists are promising vaccine adjuvants. Med Res Rev. 2024;44:1768\u201399.","journal-title":"Med Res Rev"},{"key":"4537_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","volume":"119","author":"A Ghaffari","year":"2018","unstructured":"Ghaffari A, Peterson N, Khalaj K, Vitkin N, Robinson A, Francis JA, et al. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018;119:440\u20139.","journal-title":"Br J Cancer"},{"key":"4537_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25:425\u201344.","journal-title":"Nat Rev Immunol"},{"key":"4537_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41565-023-01447-7","volume":"18","author":"P Dosta","year":"2023","unstructured":"Dosta P, Cryer AM, Dion MZ, Shiraishi T, Langston SP, Lok D, et al. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat Nanotechnol. 2023;18:1351\u201363.","journal-title":"Nat Nanotechnol"},{"key":"4537_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123690","volume":"326","author":"Y Sun","year":"2025","unstructured":"Sun Y, Nakanishi H, Huang X, Ma G, Gao XD, Xia Y. Resolve and regulate: alum nanoplatform coordinating STING availability and agonist delivery for enhanced anti-tumor immunotherapy. Biomaterials. 2025;326:123690.","journal-title":"Biomaterials"},{"key":"4537_CR27","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1039\/D2CS00998F","volume":"52","author":"L Fu","year":"2023","unstructured":"Fu L, Zhang Y, Farokhzad RA, Mendes BB, Conde J, Shi J. Passive\u2019 nanoparticles for organ-selective systemic delivery: design, mechanism and perspective. Chem Soc Rev. 2023;52:6524\u201349.","journal-title":"Chem Soc Rev"},{"key":"4537_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cytogfr.2019.02.001","volume":"45","author":"B Farran","year":"2019","unstructured":"Farran B, Pavitra E, Kasa P, Peela S, Rama Raju GS, Nagaraju GP. Folate-targeted immunotherapies: passive and active strategies for cancer. Cytokine Growth Factor Rev. 2019;45:45\u201352.","journal-title":"Cytokine Growth Factor Rev"},{"key":"4537_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s44254-024-00058-2","volume":"2","author":"L Shi","year":"2024","unstructured":"Shi L, Miao Z, Cheng Y, Zhang L. Folic acid ameliorated sevoflurane exposure-induced decrease in differentiation capacity of oligodendrocyte precursor cells. Anesthesiol Perioper Sci. 2024;2:13.","journal-title":"Anesthesiol Perioper Sci"},{"key":"4537_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101252","volume":"81","author":"B Ding","year":"2025","unstructured":"Ding B, Liu X, Li Z, Xie X, Li J, Wang J, et al. A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-\u03b2-MHC-I axis. Drug Resist Updat. 2025;81:101252.","journal-title":"Drug Resist Updat"},{"key":"4537_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487\u2013500.","journal-title":"Nat Immunol"},{"key":"4537_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114954","volume":"164","author":"S Najafi","year":"2023","unstructured":"Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164:114954.","journal-title":"Biomed Pharmacother"},{"key":"4537_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60927-7","volume":"16","author":"F Chen","year":"2025","unstructured":"Chen F, Zhang H, Li S, Ren S, Huang L, Cai Z, et al. Engineering STING nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy. Nat Commun. 2025;16:5773.","journal-title":"Nat Commun"},{"key":"4537_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","volume":"11","author":"P He","year":"2015","unstructured":"He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccines Immunother. 2015;11:477\u201388.","journal-title":"Hum Vaccines Immunother"},{"key":"4537_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-018-0305-2","volume":"18","author":"E Shardlow","year":"2018","unstructured":"Shardlow E, Mold M, Exley C. Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminumbased adjuvants and their immunological mechanisms of action. Allergy Asthma Clin Immunol. 2018;18:80.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"4537_CR36","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1016\/j.vaccine.2020.02.001","volume":"38","author":"A Colaprico","year":"2020","unstructured":"Colaprico A, Senesi S, Ferlicca F, Brunelli B, Ugozzoli M, Pallaoro M, et al. Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. Vaccine. 2020;38:3600\u20139.","journal-title":"Vaccine"},{"key":"4537_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2478\/intox-2019-0007","volume":"12","author":"IO Igbokwe","year":"2019","unstructured":"Igbokwe IO, Igwenagu E, Igbokwe NA. Aluminium toxicosis: a review of toxic actions and effects. Interdiscip Toxicol. 2019;12:45\u201370.","journal-title":"Interdiscip Toxicol"},{"key":"4537_CR38","first-page":"210","volume":"16","author":"SN Khleif","year":"2025","unstructured":"Khleif SN, Gupta S. Cancer vaccines as enablers of immunotherapy. Nat Immunol. 2025;16:210\u20138.","journal-title":"Nat Immunol"},{"key":"4537_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"4537_CR40","doi-asserted-by":"publisher","first-page":"25134","DOI":"10.1021\/acsnano.5c05395","volume":"19","author":"TMH Huynh","year":"2025","unstructured":"Huynh TMH, Huang PX, Wang KL, Tran NT, Iao HM, Pan WC, et al. Reprogramming immunodeficiency in lung metastases via PD-L1 siRNA delivery and antigen capture of nanosponge-mediated dendritic cell modulation. ACS Nano. 2025;19:25134\u201353.","journal-title":"ACS Nano"},{"key":"4537_CR41","volume":"0","author":"TMH Huynh","year":"2025","unstructured":"Huynh TMH, Tran NT, Lee YS, Chang YH, Iao HM, Pan WC, et al. Dysfunctional T Cell reprogramming via cascade-responsive catalytic nanosponges-mediated tumor-specific antigen capture for remote glioblastoma immunotherapy. Adv Funct Mater. 2025;0:e23478.","journal-title":"Adv Funct Mater"},{"key":"4537_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202502817","author":"HW Lien","year":"2025","unstructured":"Lien HW, Kuo YY, Chang YH, Huynh TMH, Yalamandala BN, Li TC, et al. Electromagnetic wireless remote control of reprogramming immune dysfunction via N-Doped carbon dots-mesoporous silica-mediated Cuproptosis and dendritic cell retention. Adv Healthc Mater. 2025. https:\/\/doi.org\/10.1002\/adhm.202502817.","journal-title":"Adv Healthc Mater"},{"key":"4537_CR43","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1016\/j.vaccine.2020.02.001","volume":"38","author":"A Colaprico","year":"2020","unstructured":"Colaprico A, Senesi S, Ferlicca F, Brunelli B, Ugozzoli M, Pallaoro M, et al. Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. Vaccine. 2020;38:3600\u20139.","journal-title":"Vaccine"},{"key":"4537_CR44","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J Exp Med. 2011;208:2005\u201316.","journal-title":"J Exp Med"},{"key":"4537_CR45","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-17-0581","volume":"6","author":"JM Diamond","year":"2018","unstructured":"Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, et al. Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol Res. 2018;6:910\u201320.","journal-title":"Cancer Immunol Res"},{"key":"4537_CR46","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830\u201342.","journal-title":"Immunity"},{"key":"4537_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006170","volume":"11","author":"N Shakfa","year":"2023","unstructured":"Shakfa N, Li D, Conseil G, Lightbody ED, Wilson-Sanchez J, Hamade A, et al. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer. J Immunother Cancer. 2023;11:e006789.","journal-title":"J Immunother Cancer"},{"key":"4537_CR48","first-page":"123","volume":"45","author":"Y Yan","year":"2025","unstructured":"Yan Y, Tan X, Song B, Yi M, Chu Q, Wu K. Breaking barriers: the cGAS-STING pathway as a novel frontier in cancer immunotherapy. Cancer Commun (Lond). 2025;45:123\u201345.","journal-title":"Cancer Commun (Lond)"},{"key":"4537_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","volume":"31","author":"J Fucikova","year":"2021","unstructured":"Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31:5\u201316.","journal-title":"Cell Res"},{"key":"4537_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091415","volume":"11","author":"AI Birmpilis","year":"2022","unstructured":"Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, Kostopoulos IV, Antimissari E, et al. Immunogenic cell death, DAMPs and prothymosin \u03b1 as a putative anticancer immune response biomarker. Cells. 2022;11:1415.","journal-title":"Cells"},{"key":"4537_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-065X.2007.00574.x","volume":"220","author":"ME Bianchi","year":"2007","unstructured":"Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007;220:35\u201346.","journal-title":"Immunol Rev"},{"key":"4537_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm2077","volume":"7","author":"A Purcarea","year":"2022","unstructured":"Purcarea A, Jarosch S, Barton J, Grassmann S, Pachmayr L, D\u2019Ippolito E, et al. Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. Sci Immunol. 2022;7:eabm2077.","journal-title":"Sci Immunol"},{"key":"4537_CR53","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41578-021-00372-2","volume":"7","author":"GA Roth","year":"2022","unstructured":"Roth GA, Picece VCTM, Ou BS, Luo W, Pulendran B, Appel EA. Designing spatial and temporal control of vaccine responses. Nat Rev Mater. 2022;7:174\u201395.","journal-title":"Nat Rev Mater"},{"key":"4537_CR54","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274.","journal-title":"Signal Transduct Target Ther"},{"key":"4537_CR55","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41563-025-02390-9","volume":"25","author":"IS Pires","year":"2026","unstructured":"Pires IS, Covarrubias G, Gomerdinger VF, Backlund C, Nombera Bueno E, Billingsley MM, et al. IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer. Nat Mater. 2026;25:322\u201334.","journal-title":"Nat Mater"},{"key":"4537_CR56","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","volume":"54","author":"BS Hanna","year":"2021","unstructured":"Hanna BS, Lla\u00f3-Cid L, Iskar M, Roessner PM, Klett LC, Wong JKL, et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity. 2021;54:2825-e284110.","journal-title":"Immunity"},{"key":"4537_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae020","volume":"11","author":"S Zhang","year":"2024","unstructured":"Zhang S, Song D, Yu W, Li J, Wang X, Li Y, et al. Combining cisplatin and a STING agonist into one molecule for metalloimmunotherapy of cancer. Natl Sci Rev. 2024;11:nwae020.","journal-title":"Natl Sci Rev"},{"key":"4537_CR58","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.2147\/IJN.S477320","volume":"19","author":"ARS Ribeiro","year":"2024","unstructured":"Ribeiro ARS, Neuper T, Horejs-Hoeck J. The role of STING-mediated activation of dendritic cells in cancer immunotherapy. International Journal of Nanomedicine. 2024;19:10685\u201397.","journal-title":"International Journal of Nanomedicine"},{"key":"4537_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk7812","volume":"9","author":"S Park","year":"2024","unstructured":"Park S, Ahn J, Barber GN. Antigen-presenting cell activation requires intrinsic and extrinsic STING signaling after the phagocytosis of DNA-damaged cells. Sci Immunol. 2024;9:eadk7812.","journal-title":"Sci Immunol"},{"key":"4537_CR60","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/2159-8290.CD-18-1357","volume":"9","author":"PA Ott","year":"2019","unstructured":"Ott PA, Wu CJ. Cancer vaccines: steering T cells down the right path to eradicate tumors. Cancer Discov. 2019;9:476\u201381.","journal-title":"Cancer Discov"},{"key":"4537_CR61","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565:234\u20139.","journal-title":"Nature"},{"key":"4537_CR62","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41590-026-02421-w","volume":"27","author":"S Frischholz","year":"2026","unstructured":"Frischholz S, Schuster EM, Grotz M, Sch\u00fclein C, Benz J, Kocher K, et al. Metabolic quiescence of naive-like memory T cells precedes and maintains antigen-specific T cell memory. Nat Immunol. 2026;27:452\u201362.","journal-title":"Nat Immunol"},{"key":"4537_CR63","volume":"02","author":"S Adamo","year":"2026","unstructured":"Adamo S, Rurik JG, Gustafson CE, Buggert M. Memory T cell aging and rejuvenation. Immunity. 2026;02:018.","journal-title":"Immunity"},{"key":"4537_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123690","volume":"326","author":"Y Sun","year":"2025","unstructured":"Sun Y, Nakanishi H, Huang X, Ma G, Gao XD, Xia Y. Resolve and regulate: alum nanoplatform coordinating STING availability and agonist delivery for enhanced anti-tumor immunotherapy. Biomaterials. 2025;326:123690.","journal-title":"Biomaterials"},{"key":"4537_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123085","volume":"317","author":"L Zhang","year":"2025","unstructured":"Zhang L, Bai J, Shen A, Zhao J, Su Z, Wang M, et al. Artificially tagging tumors with nano-aluminum adjuvant-tethered antigen mRNA recruits and activates antigen-specific cytotoxic T cells for enhanced cancer immunotherapy. Biomaterials. 2025;317:123085.","journal-title":"Biomaterials"},{"key":"4537_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2024.11.018","volume":"377","author":"D Chen","year":"2025","unstructured":"Chen D, Ling X, Wang Y, Zhang Q, He X, Dong Z, et al. Autophagy-activating aluminum hydroxide nanovaccine for enhanced antigen presentation and anti-tumor immunity. J Control Release. 2025;377:223\u201335.","journal-title":"J Control Release"},{"key":"4537_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03560-2","volume":"23","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Yin Y, Xu J, Su R, Zhang S, Han F, et al. Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity. J Nanobiotechnol. 2025;23:472.","journal-title":"J Nanobiotechnol"},{"key":"4537_CR68","unstructured":"EUROPEAN PHARMACOPOEIA-10th EDITION, European Directorate for the Quality of Medicines & HealthCare (edqm.eu). 2020;1:1. https:\/\/www.edqm.eu\/en\/web\/edqm\/european-pharmacopoeia-ph-eur-10th-edition"},{"key":"4537_CR69","unstructured":"Code of Federal Regulation. Title 21-Food and Drugs. pp. 48\u2009\u2013\u200939. https:\/\/www.fda.gov"},{"key":"4537_CR70","volume-title":"Pharmacopoeia of the People\u2019s Republic of China (3)","author":"State Pharmacopoeia Commission","year":"2015","unstructured":"State Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China (3). Beijing: China Pharmaceutical Science and Technology; 2015."}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04537-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:04:52Z","timestamp":1783303492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04537-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4537"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04537-5","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by the Animal Ethics Committee of Chongqing Medical University (IACUC-CQMU-2025-05089). All animals were treated under the Guidelines for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"620"}}